Journal Article10.1016/S0168-8278(00)80429-8
Liver-directed gene therapy: promises, problems and prospects at the turn of the century.
Siddhartha Sankar Ghosh,Masahiko Takahashi,Narsing R. Thummala,Bhupesh Parashar,Namita Roy Chowdhury,Jayanta Roy Chowdhury +5 more
TL;DR: Liver-directed gene therapy is poised to make an important impact on health care in the year 2000 and beyond and is safe to predict that gene therapy vehicles that will be in clinical use a decade from now, have not yet been developed.
read more
About: This article is published in Journal of Hepatology. The article was published on 01 Jan 2000.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Adenoviral vectors: a promising tool for gene therapy.
TL;DR: These methods include minimization or elimination of viral genes, retargeting of vector to the tissue of interest, and generation of immunocompromised recombinant vectors that lead to safer use of Ad vector systems that improve persistence of transgene expression.
146
High-throughput approaches for screening and analysis of cell behaviors.
Jungmok Seo,Jung Youn Shin,Jeroen Leijten,Oju Jeon,Gulden Camci-Unal,Anna D. Dikina,Katelyn N. Brinegar,Amir M. Ghaemmaghami,Eben Alsberg,Ali Khademhosseini +9 more
TL;DR: Recent developments in HT approaches that help identify cellular microenvironments affecting cell behaviors and highlight HT screening of biochemical libraries for gene delivery, drug discovery, and toxicological studies are described.
82
Inhibition of hepatocarcinoma by systemic delivery of Apoptin gene via the hepatic asialoglycoprotein receptor.
Peng Dj,Sun J,Wang Yz,Tian J,Zhang Yh,Zhang Yh,Mathieu H.M. Noteborn,Mathieu H.M. Noteborn,Qu S +8 more
TL;DR: The data reveal that systemic delivery of Asor–Apoptin specifically induces apoptosis in malignant hepatocytes and thus constitutes a powerful and safe therapeutics against hepatocarcinomas.
60
Clinical gene therapy for nonmalignant disease.
TL;DR: Limited evidence is found suggesting that gene therapy may benefit patients who have severe, combined, immunodeficiency disorder; cystic fibrosis; coronary artery disease or peripheral arterial disease; or hemophilia.
43
Patent
Gene regulation in transgenic animals using a transposon-based vector
Richard K. Cooper,Gary G. Cadd,William C. Fioretti,Kenneth F. Deboer +3 more
- 26 Jun 2003
TL;DR: In this article, modified transposon-based vectors have been used to achieve stable incorporation of exogenous genes into animals, and these transgenic animals produce transgenic progeny.
41
References
Model Systems for Studying the Effects of Adenovirus E3 Genes on Virulence In Vivo
TL;DR: The organ targeted for disease is often related to serotype, such that Ad7 causes pneumonia, Ad2 upper respiratory tract disease, Ad40 and Ad41 cause diarrhea, Ad11 is associated with hemorrhagic cystitis, and Ad34 and Ad35 are often found in the urinary tract of immunosuppressed patients (Horwitz 1990b).
18
HVJ-liposome mediated gene transfer into hepatocytes in vivo.
Tadamichi Hirano,Jiro Fujimoto,Takahiro Ueki,Hidenao Yamamoto,Masaharu Takeuchi,Eizo Okamoto,Hiroshi Takahashi,Ryuichi Morisita,Yoshiki Sawa,Yasufumi Kaneda +9 more
TL;DR: The results demonstrate that HVJ-liposome-mediated gene transfer produced high gene transduction and persistent gene expression in the liver.
17
Incorporation of adenovirus into a ligand-based DNA carrier system results in retention of original receptor specificity and enhances targeted gene expression
TL;DR: It is shown that adenovirus can be chemically modified by coupling ligands resulting in targeted gene expression dictated specifically by receptor recognition of the attached ligand, and specificity was retained exclusively for asialoglycoprotein receptor-bearing cells.
Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors
Richard O. Snyder,Carol H. Miao,Gijsbert A. Patijn,S. K. Spratt,Olivier Danos,D Nagy,Allen M. Gown,Brian Winther,Leonard Meuse,L. K. Cohen,Arthur R. Thompson,Mark A. Kay +11 more
TL;DR: It is demonstrated that persistent, curative concentrations of functional human factor IX can be achieved using wild-type-free and adenovirus-free rAAV vectors and demonstrates the potential of treating haemophilia B by gene therapy at the natural site of factor IX production.
Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors
TL;DR: A human lentiviral (HIV)–based vector that can transduce non-dividing cells in vitro and deliver genes In vivo is described and it is shown that the requirement for lentivirus accessory proteins to establish efficient transduction in vivo is tissue dependent.